ASCO 2020 | Repurposing irinotecan

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses a couple of abstracts presented at ASCO 2020 around repurposing irinotecan. These included the Phase I study of rucaparib and irinotecan in advanced solid tumors with homologous recombination deficiency mutations, and another Phase I study looking at the use of Pen-866, a miniature drug conjugate of a heat shock protein 90 ligand linked to SN38 for patients with advanced solid malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).